Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation

[1]  Meredith O'Keeffe,et al.  Dendritic cell subsets. , 2017, Seminars in cell & developmental biology.

[2]  P. Harden,et al.  Predictors of Cancer Risk in the Long-Term Solid-Organ Transplant Recipient , 2014, Transplantation.

[3]  Yanna Ma,et al.  Regulatory Dendritic Cells for Immunotherapy in Immunologic Diseases , 2013, Front. Immunol..

[4]  R. Lechler,et al.  Tolerogenic Donor-Derived Dendritic Cells Risk Sensitization In Vivo owing to Processing and Presentation by Recipient APCs , 2013, The Journal of Immunology.

[5]  P. Parren,et al.  Crosstalk between Human IgG Isotypes and Murine Effector Cells , 2012, The Journal of Immunology.

[6]  A. Hoitsma,et al.  Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation , 2012, Expert opinion on biological therapy.

[7]  A. Thomson,et al.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. , 2012, Blood.

[8]  P. Matzinger The evolution of the danger theory , 2012, Expert review of clinical immunology.

[9]  D. Roopenian,et al.  Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation. , 2011, Blood.

[10]  B. Malissen,et al.  Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease , 2011, Nature Medicine.

[11]  Martina L. Jones,et al.  Improved Protein-A separation of V(H)3 Fab from Fc after papain digestion of antibodies. , 2011, Journal of biomolecular techniques : JBT.

[12]  Leonard A. Smith,et al.  Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. , 2011, Protein engineering, design & selection : PEDS.

[13]  E. Elder,et al.  GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression. , 2010, Blood.

[14]  J. Marks,et al.  Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. , 2010, Journal of molecular biology.

[15]  T. Munro,et al.  A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. , 2010, Journal of immunological methods.

[16]  A. Enk,et al.  Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance? , 2009, Human immunology.

[17]  A. Palkova,et al.  Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease , 2009, The Journal of experimental medicine.

[18]  A. M. Burns,et al.  Reduced Intensity Conditioning for Allogeneic Hematopoietic Stem-Cell Transplant Determines the Kinetics of Acute Graft-Versus-Host Disease , 2008, Transplantation.

[19]  T. Mak,et al.  The CD83 reporter mouse elucidates the activity of the CD83 promoter in B, T, and dendritic cell populations in vivo , 2008, Proceedings of the National Academy of Sciences.

[20]  M. Probst-Kepper,et al.  CD83 Expression in CD4+ T Cells Modulates Inflammation and Autoimmunity1 , 2008, The Journal of Immunology.

[21]  B. Fleischer,et al.  CD83 regulates lymphocyte maturation, activation and homeostasis. , 2008, Trends in immunology.

[22]  J. Lau,et al.  Activated Circulating Dendritic Cells After Hematopoietic Stem Cell Transplantation Predict Acute Graft-Versus-Host Disease , 2007, Transplantation.

[23]  P. Carter Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[24]  Ying Tang,et al.  Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. , 2005, Journal of molecular biology.

[25]  D. Jain,et al.  Donor APCs are required for maximal GVHD but not for GVL , 2004, Nature Medicine.

[26]  K. MacDonald,et al.  Characterization of human blood dendritic cell subsets. , 2002, Blood.

[27]  B. Hock,et al.  A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. , 2001, International immunology.

[28]  M. Shlomchik,et al.  Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.

[29]  J. Gerhart,et al.  Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Gallinger,et al.  A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. , 1995, Transplantation.

[31]  Liangji Zhou,et al.  Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. , 1995, Journal of immunology.

[32]  B. Hock,et al.  Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. , 1994, Immunology.

[33]  G. Winter,et al.  Selection of phage antibodies by binding affinity. Mimicking affinity maturation. , 1992, Journal of molecular biology.

[34]  J. McKenzie,et al.  THE EFFECT OF DONOR PRETREATMENT ON INTERSTITIAL DENDRITIC CELL CONTENT AND RAT CARDIAC ALLOGRAFT SURVIVAL , 1984, Transplantation.

[35]  Fabre Jw,et al.  Mechanism of induction of passive enhancement. Evidence for an interaction of enhancing antibody with donor interstitial dendritic cells. , 1982 .

[36]  C. Bollard,et al.  Complications of transplant for nonmalignant disorders: autoimmune cytopenias, opportunistic infections, and PTLD. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  Xenia Luna,et al.  IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. , 2010, Human antibodies.

[38]  S. Giralt,et al.  Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  Masato Kato,et al.  Human T lymphoblasts and activated dendritic cells in the allogeneic mixed leukocyte reaction are susceptible to NK cell-mediated anti-CD83-dependent cytotoxicity. , 2004, International immunology.